Drug intelligence / Profile preview

Nalu-0011

Development stage: Preclinical
Lead developer: Nalu Bio
Modality: Small Molecules

Overview

Nalu-0011 is a small molecule drug candidate being developed by Nalu Bio for the treatment of metabolic and immune-related disorders. It is designed to modulate G protein-coupled receptors (GPCRs) within the endocannabinoid system (ECS). Currently in the basic research phase, the specific molecular targets and precise mechanism of action for Nalu-0011 have not been disclosed. The program is part of Nalu Bio's broader effort to develop high-purity, chemically synthesized ECS-targeted therapies that offer improved precision and consistency compared to plant-derived cannabinoids.

Targets

CB (Cannabinoid receptors)

Beyond the preview

Go deeper on Nalu-0011.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nalu-0011.

Explore the full profile